Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
2004 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Immunological aspects of cancer chemotherapy
2007
Estimating the mean and variance from the median, range, and the size of a sample
2005 Standout
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
1999
Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients
2006
Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
2008
Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis
2011
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
Delayed graft function in kidney transplantation
2004 Standout
Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis
2007
Cancer to bone: a fatal attraction
2011 Standout
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
2012
Renal cell carcinoma
2009
Application of magnetic techniques in the field of drug discovery and biomedicine
2003
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Salvage radiotherapy after prostatectomy – What is the best time to treat?
2011
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Isolation of rare circulating tumour cells in cancer patients by microchip technology
2007 StandoutNature
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
2011
The anticancer immune response: indispensable for therapeutic success?
2008
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Immunity, Inflammation, and Cancer
2010 Standout
Prevention of Venous Thromboembolism
2004 Standout
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
2011 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
2010
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
2008
Strategies to Improve Long-Term Outcomes after Renal Transplantation
2002 Standout
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
2005 Standout
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer
2001
Prevention of Venous Thromboembolism
2008 Standout
Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen
2010
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Erythropoietin for patients with malignant disease
2004
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis
2012
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Anemia of Chronic Disease
2005 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
Cell Biology of the Glomerular Podocyte
2003 Standout
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
2006
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology
2002
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice
2012 StandoutNobel
Isolation of circulating cancer cells from whole blood by immunomagnetic cell enrichment and unenriched immunocytochemistry in vitro.
2003
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)
2005
Interleukin-4 and -13 promote basolateral secretion of H+and cathepsin L by glomerular epithelial cells
2002
Immunotherapy for renal cell cancer in the era of targeted therapy
2008
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Applications of magnetic nanoparticles in biomedicine
2003 Standout
Advances in Cancer Immunotherapy in Solid Tumors
2016
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer
2002 StandoutNobel
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999 Standout
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Delayed Graft Function in Renal Transplantation: Etiology, Management and Long-term Significance
1996
Isolation of Circulating Cancer Cells From Whole Blood By Immunomagnetic Cell Enrichment and Unenriched Immunocytochemistry In Vitro
2003
Multifunctional Magnetic Nanoparticles: Design, Synthesis, and Biomedical Applications
2009 Standout
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Angiogenesis in urological malignancy: prognostic indicator and therapeutic target
1999
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
2003
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
2004
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Detection and clinical implications of early systemic tumor cell dissemination in breast cancer.
2003
Works of U. Rebmann being referenced
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
1995
Concentrations of lysosomal cysteine proteases are decreased in renal cell carcinoma compared with normal kidney
1997
Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
2006
Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation
2001
Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study
1998
Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95
2009
[The improvement of the tolerance of the kidney for ischemia with the prostacyclin analog iloprost].
1990
Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
2004